Share This Author
Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.
Current progress in the immunological measurement of the IGF is reviewed including different strategies for avoiding binding protein interference and an attempt is made to indicate circumstances in which the IGFs are exerting their actions in an autocrine/paracrine mode and when endocrine actions predominate.
Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.
- W. Daughaday, I. Mariz, S. Blethen
- Medicine, BiologyThe Journal of clinical endocrinology and…
- 1 October 1980
A simplified system of Sm extraction is developed which has permitted a quantitative comparison of native and extracted Sm, and neutral gel filtration studies established that virtually all of the binding complex was removed by acid-ethanol precipitation.
Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia.
- W. Daughaday, M. Emanuele, M. Brooks, A. Barbato, M. Kapadia, P. Rotwein
- Medicine, BiologyThe New England journal of medicine
- 1 December 1988
The most likely cause of this patient's recurrent hypoglycemia was IGF-II produced by the leiomyosarcoma, and eight months after reoperation, plasma concentrations of IGF-I and IGF-ii were normal, and high-molecular-weight IGF- II was virtually undetectable.
A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro.
Somatomedin: Proposed Designation for Sulphation Factor
The observations underlying this hypothesis have been amply confirmed and extended and a GH-dependent plasma factor stimulates in cartilage not only the incorporation of sulphate into chondroitin sulphate, but also the incorporate of thymidine into DNA and proline into the hydroxyproline of collagen.
The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors.
- W. Daughaday
- 1 July 1990
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
- O. el-Badry, C. Minniti, E. Kohn, P. Houghton, W. Daughaday, L. Helman
- Biology, MedicineCell growth & differentiation : the molecular…
- 1 July 1990
The data suggest that endogenously produced IGF-II functions as an autocrine growth and motility factor in many rhabdomyosarcoma tumors and may be mediated through an alternative signaling pathway.
Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors.
The cause of hypoglycemia in these patients may be the inability of complexes between the abnormal tumor IGF-II and IGFBP-3 to be sequestered in the biologically inactive ternary complex.
Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.
- W. Daughaday, B. Trivedi, R. Baxter
- BiologyProceedings of the National Academy of Sciences…
- 15 June 1993
It is concluded that the nonglycosylated big IGF-II of NICTH serum can form normal complexes with serum IGFBPs, and the defective binding in NICTH is attributable to defective IGFBP-3 binding.